2019
Reduced Sexual Risk Behaviors Among Persons With HIV After Release From the Criminal Justice System
Biondi BE, Frank C, Horn BP, Springer SA. Reduced Sexual Risk Behaviors Among Persons With HIV After Release From the Criminal Justice System. Open Forum Infectious Diseases 2019, 6: ofz411. PMID: 31660369, PMCID: PMC6788338, DOI: 10.1093/ofid/ofz411.Peer-Reviewed Original ResearchHIV viral suppressionViral suppressionMonths 1Double-blind placebo-controlled trialCondom usePlacebo-controlled trialExtended-release naltrexoneOpioid use disorderSelf-reported sexual activityHIV prevalenceHIV transmissionSexual intercourse eventsGeneral populationUse disordersSex partnersHIVSexual partnersAlcohol useSexual activityIntercourse eventsMonthsSexRiskMonths postreleaseSuppression
2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppression
2012
Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners. PLOS ONE 2012, 7: e38335. PMID: 22719814, PMCID: PMC3365007, DOI: 10.1371/journal.pone.0038335.Peer-Reviewed Original ResearchConceptsMaximum viral suppressionOpioid dependenceViral suppressionGlobal health qualityMaximal viral suppressionHIV treatment outcomesBuprenorphine/naloxoneCopies/mLChronic relapsing diseaseDSM-IV criteriaAntiretroviral therapyOpioid useProspective trialProspective studyRelapsing diseaseOpioid dependentsTreatment outcomesHIV-1HIVNLXHealth qualityTherapyWeeksSuppressionGroup